查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2052619

急性腎損傷（AKI）：市場展望、流行病學、競爭格局、市場預測報告（2025-2035年）

Acute Kidney Injury (AKI) - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035
出版日期: | 出版商: Thelansis Knowledge Partners | 英文 155 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

市場概覽

  • 預計到2035年，德國 AKI 市場將從約 1.05億美元成長到 2.3億美元。
  • 以下因素推動市場成長：
  • 住院率和加護病房使用率不斷上升
  • 擴大腎功能監測和支持性治療的應用範圍。
  • 市場擴張的驅動力在於人們對預防和治療腎臟損傷的認知不斷提高。
  • 未來的成長將取決於新的腎臟保護療法和早期診斷技術。

急性腎損傷（AKI）概述

急性腎損傷（AKI）是指腎功能快速且可能可逆的下降，其特徵是腎小球濾過率急劇下降、氮血症，並常伴隨少尿。根據KDIGO標準，AKI根據血清肌酸酐水準和尿量閾值分為三個嚴重程度階段。其病理生理機轉包括腎前性（由體液容量不足、膿毒症或心腎症候群引起的血流動力學不全）、腎實質（由缺血、腎毒性物質、腎小球腎炎或間質性腎炎引起的腎小管損傷）和腎後性（梗阻性尿路疾病），其中急性腎小管壞死是最常見的腎後性病因。患者臨床表現為尿量減少、體液超負荷、電解質失衡（高血鉀、代謝性酸中毒、低血鈉），嚴重者可出現尿毒症症狀。診斷包括監測血清肌酸酐水準和尿量、尿液顯微鏡尿液檢查、腎臟超音波檢查以及針對病因的標靶檢查（補體、ANCA、抗腎小球基底膜抗體檢測等），必要時進行切片檢查。治療主要以支持治療為主，包括血流動力學最佳化、清除腎毒性物質、體液平衡管理、電解質矯正以及針對原發病因進行治療。對於難治性高血鉀、代謝性酸中毒、體液超負荷或尿毒症併發症，需啟動腎臟替代治療。新型生物標記（NGAL、KIM-1、TIMP-2/IGFBP-7）能夠實現急性腎損傷（AKI）的早期檢測和風險分層。預後取決於病因和嚴重程度。倖存者發生慢性腎臟病、心血管事件和AKI復發的風險較高，因此需要進行系統性的腎臟病追蹤和以患者為中心的長期腎功能監測。

主要亮點

  • 根據預測，德國急性腎損傷（AKI）新病例數將從2025年的約 152,260 例增加到2035年的155,034 例。
  • 急性腎損傷仍然是住院的主要原因之一，並且與顯著的發病率、死亡率和醫療保健負擔有關。
  • 老年患者和慢性腎臟病患者仍然是高危險群。
  • 早期診斷和及時介入對於預防發展為慢性腎臟病和腎衰竭非常重要。
  • 由於生物標記監測和重症監護管理的日益普及，患者的治療效果改善。

格式化和更新訊息

  • 詳細報告（PDF）
  • 市場預測模型（基於MicrosoftExcel）
  • 流行病學資料（MS Excel，互動式工具）
  • 高層洞察（PPT簡報）
  • 其他功能：定期更新、自訂和顧問支援。
  • 根據 Thelansis 的政策，確保所有最新更新在發布前都反映在報告內容和市場模型中。

主要問題

  • 如何最佳化 G8 市場（美國、歐盟 5 國、日本、中國）的藥物開發與生命週期管理策略？
  • 從發病率、盛行率、人群組成以及接受藥物治療的患者人數來看，患者數量分別是多少？
  • 未來十年市場收入和病患佔有率的預測是多少？
  • 哪些因素對市場趨勢影響最大？
  • 受訪專家對目前和新興的治療方法有何看法？
  • 哪款在研發線產品最有前景？其上市潛力及未來市場定位如何？
  • 主要未被滿足的需求是什麼？ KOL 對目標受眾有何期望？
  • 為確保藥物核准並順利進入市場，必須滿足哪些關鍵的監管和支付方要求？

目標國家

  • G8
    • 美國
    • EU5
      • 法國
      • 德國
      • 義大利
      • 西班牙
      • 英國
    • 日本
    • 中國

主要企業

  • M2RLAB SL
  • Hope Biosciences LLC
  • CalciMedica, Inc.
  • AstraZeneca
  • Arch Biopartners Inc.
  • Novartis Pharmaceuticals
  • EnnovaBio
  • Bilix Co., Ltd.
  • Noorik Biopharmaceuticals AG
  • Vantive Health LLC

目錄

第1章 主要調查結果及分析師說明

  • 主要趨勢：市場概況、SWOT分析、商業性利益與風險等。

第2章 疾病背景

  • 疾病定義、分類、病因和病理生理學、藥物標靶等。

第3章 流行病學

  • 重點
  • 發病率/盛行率
  • 已確診並接受藥物治療的患者人數
  • 合併症
  • 其他相關患者群

第4章 市場規模及預測

  • 重點
  • 市場促進因素與限制因素
  • 依藥物類別分類的趨勢
  • 各國具體趨勢

第5章 競爭情勢

  • 目前的治療方法
  • 重點
  • 診斷和治療過程/演算法
  • 主要治療方法概述及KOL洞察
  • 新興治療方法
  • 重點
  • 值得關注的後期新治療方法 - 概述、市場上市預期及KOL洞察
  • 值得關注的早期管道

第6章 未滿足的需求與目標產品分析

  • 主要未滿足的需求以及透過新興治療方法實現的未來可能性
  • TPP分析與KOL展望

第7章 監理與償付環境

第8章 附錄

簡介目錄

Acute Kidney Injury (AKI) Market Outlook

Thelansis's "Acute Kidney Injury (AKI) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Acute Kidney Injury treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Acute Kidney Injury (AKI) Overview

Acute kidney injury (AKI) is a rapid, potentially reversible decline in renal function characterised by abrupt reduction in glomerular filtration rate, azotaemia, and frequently oliguria, classified by KDIGO criteria into three severity stages based on serum creatinine rise and urine output thresholds. The pathophysiology encompasses prerenal - haemodynamic insufficiency from volume depletion, sepsis, or cardiorenal syndrome - intrinsic renal - tubular injury from ischaemia or nephrotoxins, glomerulonephritis, or interstitial nephritis - and postrenal - obstructive uropathy - mechanisms, with acute tubular necrosis representing the most prevalent intrinsic aetiology. Patients present with declining urine output, fluid overload, electrolyte disturbances - hyperkalaemia, metabolic acidosis, hyponatraemia - and uraemic symptoms in severe cases. Diagnosis integrates serum creatinine and urine output trajectory, urinalysis with microscopy, renal ultrasonography, and targeted investigations addressing aetiology - including complement, ANCA, anti-GBM antibodies, and renal biopsy where indicated. Management is predominantly supportive - optimising haemodynamics, eliminating nephrotoxins, managing fluid balance, correcting electrolyte derangements, and addressing the underlying cause; renal replacement therapy is instituted for refractory hyperkalaemia, metabolic acidosis, volume overload, or uraemic complications. Emerging biomarkers - NGAL, KIM-1, and TIMP-2/IGFBP-7 - facilitate earlier AKI detection and risk stratification. Prognosis varies with aetiology and severity; survivors carry elevated risks of chronic kidney disease progression, cardiovascular events, and recurrent AKI, necessitating structured nephrology follow-up and patient-centred long-term renal surveillance.

Key Highlights

  • In Germany, incident AKI cases are projected to increase from approximately 152,260 in 2025 to 155,034 by 2035.
  • AKI remains a major cause of hospitalization and is associated with significant morbidity, mortality, and healthcare burden.
  • Elderly patients and individuals with chronic kidney disease continue to represent high-risk populations.
  • Early diagnosis and timely intervention are critical to preventing progression to chronic kidney disease and kidney failure.
  • Increasing adoption of biomarker-based monitoring and critical care management is improving patient outcomes.

Market Overview

  • The Germany AKI market is projected to grow from approximately $105 MN to $230 MN by 2035.
  • Market growth is supported by:
  • Rising hospitalization rates and critical care utilization
  • Increasing adoption of renal monitoring and supportive therapies
  • Market expansion is driven by growing awareness of kidney injury prevention and management.
  • Future growth will depend on novel renal protective therapies and early diagnostic technologies.

Insights driven by robust research, including:

  • In-depth interviews with leading KOLs and payers
  • Physician surveys
  • RWE analysis for claims and EHR datasets
  • Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

  • Detailed Report (PDF)
  • Market Forecast Model (MS Excel-based automated dashboard)
  • Epidemiology (MS Excel; interactive tool)
  • Executive Insights (PowerPoint presentation)
  • Others: regular updates, customizations, consultant support
  • As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

  • 10-year market forecast (2025-2035)
  • Bottom-up patient-based market forecasts validated through the top-down sales methodology
  • Covers clinically and commercially-relevant patient populations/ line of therapies
  • Annualized drug-level sales and patient share projections
  • Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
  • Detailed methodology/sources & assumptions
  • Graphical and tabular outputs
  • Users can customize the model based on requirements

Key business questions answered:

  • How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
  • How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
  • What is the 10-year market outlook for sales and patient share?
  • Which events will have the greatest impact on the market's trajectory?
  • What insights do interviewed experts provide on current and emerging treatments?
  • Which pipeline products show the most promise, and what is their potential for launch and future positioning?
  • What are the key unmet needs and KOL expectations for target profiles?
  • What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

  • G8
    • United States
    • EU5
      • France
      • Germany
      • Italy
      • Spain
      • U.K.
    • Japan
    • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

  • M2RLAB SL
  • Hope Biosciences LLC
  • CalciMedica, Inc.
  • AstraZeneca
  • Arch Biopartners Inc.
  • Novartis Pharmaceuticals
  • EnnovaBio
  • Bilix Co., Ltd.
  • Noorik Biopharmaceuticals AG
  • Vantive Health LLC

Table of Contents

1. Key Findings and Analyst Commentary

  • Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

  • Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

  • Key takeaways
  • Incidence / Prevalence
  • Diagnosed and Drug-Treated populations
  • Comorbidities
  • Other relevant patient segments

4. Market Size and Forecast

  • Key takeaways
  • Market drivers and constraints
  • Drug-class specific trends
  • Country-specific trends

5. Competitive Landscape

  • Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies - profiles and KOL insights
  • Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

  • Top unmet needs and future attainment by emerging therapies
  • TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)